Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 2/2014

01-04-2014

An Alternative Pathway Through the Fenton Reaction for the Formation of Advanced Oxidation Protein Products, a New Class of Inflammatory Mediators

Authors: Guilherme Vargas Bochi, Vanessa Dorneles Torbitz, Lara Peruzzolo Cargnin, José Antonio Mainardi de Carvalho, Patrícia Gomes, Rafael Noal Moresco

Published in: Inflammation | Issue 2/2014

Login to get access

Abstract

The accumulation of advanced oxidation protein products (AOPPs) has been linked to several pathological conditions, and their levels are formed during oxidative stress as a result of reactions between plasma proteins and chlorinated oxidants produced by myeloperoxidase (MPO). However, it was suggested that the generation of this mediator of inflammation may also occur via an MPO-independent pathway. The aim of this study was to induce the formation of AOPPs in vitro through Fenton reaction and to investigate whether this generation could be counteracted by N-acetylcysteine (NAC) and fructose-1,6-bisphosphate (FBP). The complete Fenton system increased the AOPPs levels and both NAC and FBP were capable of inhibiting the formation of Fenton reaction-induced AOPPs. These data provide a new hypothesis about another pathway of AOPPs formation, as well as report that NAC and FBP may be good candidates to neutralize pro-inflammatory and pro-oxidant effects of AOPPs in several diseases.
Literature
1.
Halliwell, B. 2012. Free radicals and antioxidants: updating a personal view. Nutrition Reviews 70: 257–265.PubMedCrossRef
2.
Ray, P.D., B.W. Huang, and Y. Tsuji. 2012. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cellular Signalling 24: 981–990.PubMedCentralPubMedCrossRef
3.
Sorescu, D., D. Weiss, B. Lassegue, R.E. Clempus, K. Szocs, G.P. Sorescu, L. Valppu, M.T. Quinn, J.D. Lambeth, J.D. Vega, W.R. Taylor, and K.K. Griendling. 2002. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429–1435.PubMedCrossRef
4.
Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.PubMedCrossRef
5.
Kaneda, H., J. Taguchi, K. Ogasawara, T. Aizawa, and M. Ohno. 2002. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162: 221–225.PubMedCrossRef
6.
Kalousova, M., J. Skrha, and T. Zima. 2002. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiological Research 51: 597–604.PubMed
7.
Witko-Sarsat, V., M. Friedlander, C. Capeillere-Blandin, T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.PubMedCrossRef
8.
Guo, Z.J., H.X. Niu, F.F. Hou, L. Zhang, N. Fu, R. Nagai, X. Lu, B.H. Chen, Y.X. Shan, J.W. Tian, R.H. Nagaraj, D. Xie, and X. Zhang. 2008. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxidants and Redox Signaling 10: 1699–1712.PubMedCrossRef
9.
Zhou, L.L., W. Cao, C. Xie, J. Tian, Z. Zhou, Q. Zhou, P. Zhu, A. Li, Y. Liu, T. Miyata, F.F. Hou, and J. Nie. 2012. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney International 82: 759–770.PubMedCrossRef
10.
Himmelfarb, J., and E. McMonagle. 2001. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney International 60: 358–363.PubMedCrossRef
11.
Mera, K., M. Anraku, K. Kitamura, K. Nakajou, T. Maruyama, and M. Otagiri. 2005. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochemical and Biophysical Research Communications 334: 1322–1328.PubMedCrossRef
12.
Shi, X.Y., F.F. Hou, H.X. Niu, G. Wang, D. Xie, Z.J. Guo, Z.M. Zhou, F. Yang, J.W. Tian, and X. Zhang. 2008. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149: 1829–1839.PubMedCrossRef
13.
Zhou, L.L., F.F. Hou, G.B. Wang, F. Yang, D. Xie, Y.P. Wang, and J.W. Tian. 2009. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney International 76: 1148–1160.PubMedCrossRef
14.
Hanasand, M., R. Omdal, K.B. Norheim, L.G. Gøransson, C. Brede, and G. Jonsson. 2012. Improved detection of advanced oxidation protein products in plasma. Clinica Chimica Acta 413: 901–906.CrossRef
15.
Capeillère-Blandin, C., V. Gausson, B. Descamps-Latscha, and V. Witko-Sarsat. 2004. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta 1689: 91–102.PubMedCrossRef
16.
Capeillère-Blandin, C., V. Gausson, A.T. Nguyen, B. Descamps-Latscha, T. Drüeke, and V. Witko-Sarsat. 2006. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 21: 1555–1563.CrossRef
17.
Bochi, G.V., V.D. Torbitz, L.P. Cargnin, M.B. Sangoi, R.C. Santos, P. Gomes, and R.N. Moresco. 2012. Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro. Inflammation 35: 1786–1792.PubMedCrossRef
18.
Holmes, R.S., and C.J. Masters. 1970. Epigenetic interconversion of the multiple forms of mouse liver catalase. FEBS Letters 11: 45–48.PubMedCrossRef
19.
Witko-Sarsat, V., T. Nguyen Khoa, P. Jungers, T. Drüeke, and B. Descamps-Latscha. 1998. Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Advances in nephrology from the Necker Hospital 28: 321–341.PubMed
20.
Kalousová, M., J. Skrha, and T. Zima. 2002. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiological Research 51: 597–604.PubMed
21.
Martín-Gallán, P., A. Carrascosa, M. Gussinyé, and C. Domínguez. 2003. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radical Biology and Medicine 34: 1563–1574.PubMedCrossRef
22.
Tabak, O., R. Gelisgen, H. Erman, F. Erdenen, C. Muderrisoglu, H. Aral, and H. Uzun. 2011. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clinical and Investigative Medicine 34: 163–171.
23.
Chen, S., L. Liu, X. Sun, Y. Liu, and T. Son. 2005. Captopril restores endothelium-dependent relaxation induced by advanced oxidation protein products in rat aorta. Journal of Cardiovascular Pharmacology 46: 803–809.PubMedCrossRef
24.
Drüeke, T., V. Witko-Sarsat, Z. Massy, B. Descamps-Latscha, A.P. Guerin, S.J. Marchais, V. Gausson, and G.M. London. 2002. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212–2217.PubMedCrossRef
25.
Anraku, M., K. Kitamura, R. Shintomo, K. Takeuchi, H. Ikeda, J. Nagano, T. Ko, K. Mera, K. Tomita, and M. Otagiri. 2008. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. Clinical Biochemistry 41: 1168–1174.PubMedCrossRef
26.
Halliwell, B. 1978. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Its role in degradation of hyaluronic acid by a superoxide-generating system. FEBS Letters 96: 238–242.PubMedCrossRef
27.
Rooyakkers, T.M., E.S. Stroes, M.P. Kooistra, E.E. Van Faassen, R.C. Hider, T.J. Rabelink, and J.J. Marx. 2002. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. European Journal of Clinical Investigation 32: 9–16.PubMedCrossRef
28.
Tovbin, D., D. Mazor, M. Vorobiov, C. Chaimovitz, and N. Meyerstein. 2002. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. American Journal of Kidney Diseases 40: 1005–1012.PubMedCrossRef
29.
Stępniak, J., A. Lewiński, and M. Karbownik-Lewińska. 2013. Membrane lipids and nuclear DNA are differently susceptive to Fenton reaction substrates in porcine thyroid. Toxicology In Vitro 27: 71–78.PubMedCrossRef
30.
Valko, M., C.J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur. 2006. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions 160: 1–40.PubMedCrossRef
31.
Repka, T., and R.P. Hebbel. 1991. Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. Blood 78: 2753–2758.PubMed
32.
Trachootham, D., W. Lu, M.A. Ogasawara, R.D. Nilsa, and P. Huang. 2008. Redox regulation of cell survival. Antioxidants and Redox Signaling 10: 1343–1374.PubMedCentralPubMedCrossRef
33.
Pellegrino, P., B. Mallet, S. Delliaux, Y. Jammes, R. Gieu, and O. Schaf. 2011. Zeolites are effective ROS-scavengers in vitro. Biochemical and Biophysical Research Communications 410: 478–483.PubMedCrossRef
34.
Witko-Sarsat, V., V. Gausson, A.T. Nguyen, M. Touam, T. Drüeke, F. Santangelo, and B. Descamps-Latscha. 2003. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney International 64: 82–91.PubMedCrossRef
35.
Aruoma, O.I., B. Halliwell, B.M. Hoey, and J. Butler. 1989. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radical Biology and Medicine 6: 593–597.PubMedCrossRef
36.
Fishbane, S. 2008. N-Acetylcysteine in the prevention of contrast-induced nephropathy. Clinical Journal of the American Society of Nephrology 3: 281–287.PubMedCrossRef
37.
Holt, S., R. Marley, B. Fernando, D. Harry, R. Anand, D. Goodier, and K. Moore. 1999. Acute cholestasis-induced renal failure: Effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney International 55: 271–277.PubMedCrossRef
38.
Santos, R.C., R.N. Moresco, M.A. Peña Rico, A.R. Susperregui, J.L. Rosa, R. Bartrons, F. Ventura, D.N. Mário, S.H. Alves, E. Tatsch, H. Kober, R.O. de Mello, P. Scherer, H.B. Dias, and J.R. de Oliveira. 2012. Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease. Inflammation 35: 1256–1261.PubMedCrossRef
39.
de Mello, R.O., A. Lunardelli, E. Caberlon, C.M. de Moraes, R. Christ Vianna Santos, V.L. da Costa, G.V. da Silva, P. da Silva Scherer, L.E. Buaes, D.A. da Silva Melo, M.V. Donadio, F.B. Nunes, and J.R. de Oliveira. 2011. Effect of N-acetylcysteine and fructose-1,6-bisphosphate in the treatment of experimental sepsis. Inflammation 34: 539–550.PubMedCrossRef
40.
Alva, N., T. Carbonell, T. Roig, J. Bermúdez, and J. Palomeque. 2011. Fructose 1,6 biphosphate administration to rats prevents metabolic acidosis and oxidative stress induced by deep hypothermia and rewarming. European Journal of Pharmacology 659: 259–264.PubMedCrossRef
41.
Bajić, A., J. Zakrzewska, D. Godjevac, P. Andjus, D.R. Jones, M. Spasić, and I. Spasojević. 2011. Relevance of the ability of fructose 1,6-bis(phosphate) to sequester ferrous but not ferric ions. Carbohydrate Research 346: 416–420.PubMedCrossRef
42.
Wei, X.F., Q.G. Zhou, F.F. Hou, B.Y. Liu, and M. Liang. 2009. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. American Journal of Physiology. Renal Physiology 296: 427–437.CrossRef
43.
Zhou, Q.G., M. Zhou, A.J. Lou, D. Xie, and F.F. Hou. 2010. Advanced oxidation protein products induce inflammatory response and insulin resistance in cultured adipocytes via induction of endoplasmic reticulum stress. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 26: 775–786.CrossRef
44.
Cao, W., J. Xu, Z.M. Zhou, G.B. Wang, F.F. Hou, and J. Nie. 2013. Advanced oxidation protein products activate intrarenal renin–angiotensin system via a CD36-mediated, redox-dependent pathway. Antioxidants and Redox Signaling 18: 19–35.PubMedCentralPubMedCrossRef
45.
Valente, A.J., T. Yoshida, R.A. Clark, P. Delafontaine, U. Siebenlist, and B. Chandrasekar. 2013. Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling. Free Radical Biology and Medicine 60: 125–135.PubMedCrossRef
46.
Prousek, J. 2007. Fenton chemistry in biology and medicine. Pure and applied chemistry 79: 2325–2338.CrossRef
47.
Repetto, M.G., N.F. Ferrarotti, and A. Boveris. 2010. The involvement of transition metal ions on iron-dependent lipid peroxidation. Archives of Toxicology 84: 255–262.PubMedCrossRef
48.
González, F.B., S. Llesuy, and A. Boveris. 1991. Hydroperoxide-initiated chemiluminescence: Assay for oxidative stress in biopsies of heart, liver and muscle. Free Radical Biology and Medicine 10: 93–100.CrossRef
49.
Chance, B., H. Sies, and A. Boveris. 1979. Hydroperoxide metabolism in mammalian organs. Physiological Reviews 59: 527–605.PubMed
50.
Marsche, G., S. Frank, A. Hrzenjak, M. Holzer, S. Dirnberger, C. Wadsack, H. Scharnagl, T. Stojakovic, A. Heinemann, and K. Oettl. 2009. Plasma-advanced oxidation products are potent high-density lipoprotein receptor antagonists in vivo. Circulation Research 104: 750–757.
Metadata
Title
An Alternative Pathway Through the Fenton Reaction for the Formation of Advanced Oxidation Protein Products, a New Class of Inflammatory Mediators
Authors
Guilherme Vargas Bochi
Vanessa Dorneles Torbitz
Lara Peruzzolo Cargnin
José Antonio Mainardi de Carvalho
Patrícia Gomes
Rafael Noal Moresco
Publication date
01-04-2014
Publisher
Springer US
Published in
Inflammation / Issue 2/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9765-1

Other articles of this Issue 2/2014

Inflammation 2/2014 Go to the issue

OriginalPaper

Nickel Induces Interleukin-1β Secretion via the NLRP3–ASC–Caspase-1 Pathway

OriginalPaper

Effects of Salicylate on the Inflammatory Genes Expression and Synaptic Ultrastructure in the Cochlear Nucleus of Rats

OriginalPaper

Increased Concentration of C-Reactive Protein in Obese Patients with Type 2 Diabetes Is Associated with Obesity and Presence of Diabetes but Not with Macrovascular and Microvascular Complications or Glycemic Control

OriginalPaper

Anti-septic Effects of Pellitorine in HMGB1-Induced Inflammatory Responses In Vitro and In Vivo

OriginalPaper

First Evidence for the Anti-inflammatory Activity of Fucoxanthin in High-Fat-Diet-Induced Obesity in Mice and the Antioxidant Functions in PC12 Cells

OriginalPaper

Grape Seed Proanthocyanidin Extract Protects Against Carrageenan-Induced Lung Inflammation in Mice Through Reduction of Pro-inflammatory Markers and Chemokine Expressions
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits